Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Martin Šíma
 + 1742 word(s) 1742 2021-04-22 09:04:04 |
2 format correct
Catherine Yang
 -3 word(s) 1739 2021-04-22 11:19:05 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Šíma, M. Phenobarbital Pharmacokinetics in Neonates. Encyclopedia. Available online: https://encyclopedia.pub/entry/8907 (accessed on 15 November 2024).
Šíma M. Phenobarbital Pharmacokinetics in Neonates. Encyclopedia. Available at: https://encyclopedia.pub/entry/8907. Accessed November 15, 2024.
Šíma, Martin. "Phenobarbital Pharmacokinetics in Neonates" Encyclopedia, https://encyclopedia.pub/entry/8907 (accessed November 15, 2024).
Šíma, M. (2021, April 22). Phenobarbital Pharmacokinetics in Neonates. In Encyclopedia. https://encyclopedia.pub/entry/8907
Šíma, Martin. "Phenobarbital Pharmacokinetics in Neonates." Encyclopedia. Web. 22 April, 2021.
Phenobarbital Pharmacokinetics in Neonates
Edit
This entry is adapted from the peer-reviewed paper 10.3390/pharmaceutics13030301

Phenobarbital is a first-line treatment of various seizure types in newborns. Dosage individualization maximizing the proportion of patients with drug levels in therapeutic range or sufficient treatment response is still challenging. The available evidence on phenobarbital pharmacokinetics in neonates and its possible covariates suitable for individualization of initial drug dosing was therefore summarized.

phenobarbital pharmacokinetics neonates dosing covariates asphyxia hypoxic-ischemic encephalopathy

1. Introduction

Neonatal seizures belong among the most common serious neurological disorders worldwide [1]. The incidence of neonatal seizures is estimated between 0.7 to 2.7 per 1000 live term births and increases by two orders of magnitude to 57.5–132 per 1000 live births in preterm neonates [1]. Although there are several anti-seizure drugs available, phenobarbital still remains the first-line agent for the treatment of neonatal seizures [2]. The drug has several favorable features that include undisputed efficacy against a broad spectrum of seizure types, low risk of serious acute adverse drug reactions, multiple pathways involved in the drug elimination as well as availability of parenteral drug formulations and low cost [2]. As suggested by pre-clinical evidence, phenobarbital could have synergistic neuroprotective effects when applied with therapeutic hypothermia [3], which is now considered a standard management for term newborns with moderate to severe encephalopathy [4]. However, long-term outcome benefits have not been fully elucidated on the clinical level yet. Few reports have indicated no improvement of short-term neurodevelopmental outcomes in infants treated for neonatal seizures [5]. On the other hand, phenobarbital also displays several undesirable characteristics that limit its clinical utility. First, there is a significant interpatient variability in the treatment response, which has been confirmed in the clinical studies. Substantial subpopulations of newborns do not respond adequately to phenobarbital treatment and it is not possible to predict inadequate level of responsiveness a priori [6]. Furthermore, there are concerns that phenobarbital may negatively impact psychomotor development and neurological outcomes [7].

2. Phenobarbital Pharmacokinetics

Phenobarbital can be administered intravenously, intramuscularly, rectally, or perorally [8]. Summary of the product characteristics states that there is almost complete absorption with Tmax of 0.5–4 h after oral administration in adults, while only 48.9% bioavailability was reported in neonates [9]. Phenobarbital distribution in the body is characterized by a volume of distribution (Vd) that ranges between 0.48 and 1.56 L/kg in neonates [8][10]. The drug is 40–60% bound to plasma proteins in older children and adults [11], but two- to four-fold less in neonates [12]. The degree of protein-binding subsequently increases as a function of age [13]. Elimination (metabolism and excretion) is characterized by drug clearance (CL). Mean phenobarbital CL values range from 0.0021 to 0.0076 L/h/kg in neonates, which is (together with Vd) reflected in the mean t1/2 values of 82–298 h [8][10]. About 25% of drug dose administered is excreted unchanged via urine, while its major proportion is metabolized, principally by oxidation catalyzed by 2C9 enzyme of cytochrome P450 (CYP) with minor contributions of CYP2C19, CYP2E1, and N-glucosidation [14]. Phenobarbital displays pharmacokinetics linearly related to the dose administered [15].

Loading and maintenance doses of phenobarbital can be calculated from its Vd and total CL, respectively [16]. In clinical practice, the treatment is usually initiated by intravenous loading dose of 20 mg/kg. If seizures persist, additional bolus doses of 5–10 mg/kg can be administered at 20–30 minutes intervals up to a total dose of 40 mg/kg. Maintenance doses of 3–4 mg/kg/day are commenced 12–24 h after loading dose [17]. However, various studies in the past have used considerably variable dosing schemes using loading doses between 7–20 mg/kg and maintenance doses between 1.3–7.5 mg/kg [18][19][20]. Routine therapeutic drug monitoring (TDM) is recommended during phenobarbital treatment to reach and maintain drug levels in the target therapeutic range, since high pharmacokinetic variability has been reported [21]. Despite the drug being used since 1912, there is no clear consensus on the optimal therapeutic levels to be attained, although phenobarbital levels between 10 and 40 mg/L most likely represent favorable drug exposure. Jalling estimated the therapeutic range of phenobarbital concentration when convulsions ceased of 12–30 mg/L [22], while other studies targeted at a range of 10–30 mg/L [23][24], 20–25 mg/L [25][26], or 15–40 mg/L [19][20][27][28]. TDM-based dose adjustment is feasible only after pharmacotherapy has been introduced, while relatively wide range of doses can be used at the beginning of therapy. Therefore, the identification of suitable covariates for phenobarbital pharmacokinetics allowing dosage individualization with subsequently increased proportion of patients attaining drug levels in the target therapeutic range could be beneficial.

3. Covariates of Phenobarbital Pharmacokinetics

3.1. Demographics

The most frequently considered covariates for phenobarbital pharmacokinetics in neonates were actual body weight (ABW), gestational, and postnatal age.

Some studies have indicated these demographic descriptors as significant covariates for phenobarbital CL [23][29][30]. In addition, Touw et al. also described an association of height and body surface area with Vd and CL, respectively [23]. However, other studies have indicated rather inconsistent data, making conclusions on valid covariates for the drug dosing difficult. We have previously noticed an upward relationship between Vd and ABW, height, and body surface area, whereas CL was not associated with either demographic or clinical features [31]. Pitlick et al. observed no correlation between Vd and gestational age, while CL increased with postnatal age during the first month [32]. Grasela et al. showed that neither Vd nor CL was affected by gestational age [33]. Gilman et al. found no correlation between half-life and either gestational or postnatal age [18]. The study of Völler et al. presented birthweight and postnatal age as the best predictors for maturation of phenobarbital CL and ABW as a predictor for Vd [34]. Moffett et al. showed that significant covariates included fat-free mass (FFM) and postmenstrual age on CL, and FFM and postnatal age on Vd across the pediatric age populations [35]. Back et al. proposed a population nonlinear mixed effect pharmacokinetic, modeling size and maturation functions as covariates of phenobarbital dispositions [36]. In neonates and young infants, both size and maturation functions application was more effective for pharmacokinetic analysis than when only size function was considered. Similar methods and findings have been shown by Thibault et al., where ABW and postnatal age were found as covariates of CL, while ABW predicted phenobarbital Vd [37]. However, this mixed effect approach is relatively exacting and therefore is unlikely to find an application in daily practice.

3.2. Laboratory Parameters

No relationships have been observed between laboratory markers of liver functions (total bilirubin, aspartate aminotransferase, alanine aminotransferase, international normalized ratio) and phenobarbital disposition [31][30][35]. In contrast, a recent study using a nonlinear mixed effect approach has described that albumin increases phenobarbital Vd [37]. From the laboratory markers of renal functions, levels of serum urea, serum creatinine, and blood urea nitrogen (BUN) were tested. Urea level was not found to be a significant covariate for the phenobarbital CL. Additionally, creatinine was also not found to be a significant descriptor of the phenobarbital CL variability [31][38][39], while Moffett et al. described a relationship between serum creatinine and phenobarbital CL [35]. As inflammation can influence CYP450 enzyme activity, the C-reactive protein (CRP) level was also tested as a predictor of phenobarbital CL in the critically-ill neonates undergoing ECMO (47), but no relation was found.

3.3. Asphyxia

The impact of asphyxia has also been studied, but with contradictory results. Gal et al. reported CL reduction in asphyxiated neonates [40][41], while Grasela et al. noticed no effect on CL, while increased Vd was noted in the presence of asphyxia [33]. Pokorna et al. presented severity of asphyxia as a covariate of phenobarbital CL in patients undergoing therapeutic hypothermia [42], but no effect of asphyxia and its severity on the drug pharmacokinetics was shown in a relatively similar patient population using a population pharmacokinetic modeling approach [43].

3.4. Therapeutic Modalities

Therapeutic modalities potentially affecting phenobarbital pharmacokinetics that have been studied are therapeutic hypothermia, renal replacement therapy (RRT), and extracorporeal membrane oxygenation (ECMO). Shellhaas et al., van den Broek et al., and Favie et al. have not identified any impact of hypothermia on the phenobarbital disposition [30][44][45]. Although Filippi et al. stated that phenobarbital administered to newborns under whole body hypothermia resulted in higher plasma concentrations and longer half-lives than expected in normothermic newborns, this study did not contain any normothermic control group, making comparison of the pharmacokinetics between the hypo- and normo-thermic neonates impossible [27]. Thus, the effect of therapeutic hypothermia does not seem to be clinically relevant for phenobarbital dosing. A recent study has found that interaction of severity of asphyxia and hypothermia is associated with a clinically relevant reduction of phenobarbital CL, suggesting the potential relevance of disease characteristics beyond hypothermia itself [42].

Pokorna et al. observed increased phenobarbital CL in neonates receiving ECMO support, while Vd was not significantly different compared to neonates without ECMO [46]. These observations are consistent with the necessity of higher doses in ECMO patients described by Dillman et al. [47]. Thibault et al. reported the effect of ECMO therapy on phenobarbital Vd in neonates after congenital heart surgery, resulting in the need for a higher loading dose, but the drug CL was not affected [37]. In another study, the same research group found a 6-fold increase of phenobarbital CL in neonates and infants undergoing continuous veno-venous hemodiafiltration (CVVHDF) compared to the neonates and infants without CVVHDF. Additionally, the authors found no impact of ECMO on phenobarbital Vd. When analyzed phenobarbital levels before, during, and after ECMO, Michaličková et al. observed that phenobarbital CL linearly increased with time during the ECMO phase, while in the post-ECMO phase, CL initially decreased and subsequently increased slowly, which was likely driven by maturation [38]. Moreover, the authors found no impact of ECMO on phenobarbital Vd. Thus, data indicated that higher phenobarbital doses are needed during ECMO, however, the particular dosing recommendation varied.

3.5. Drug Interactions and Genetic Polymorphisms

Impact of the co-medication of several drugs on phenobarbital pharmacokinetics has been investigated repeatedly [33][44][45][48][47]. No significant effect of co-administered dopamine, dobutamine, norepinephrine, phenytoin, sufentanil, midazolam, tramadol, or furosemide was observed in short-term concomitant treatment [48]. Michaličková et al. also did not observe any effect of diuretics and inotrope use on phenobarbital CL in critically-ill neonates undergoing ECMO [44]. Although Moffett et al. concluded that midazolam, phenytoin, and pantoprazole significantly affected phenobarbital CL [35], this finding has been questioned as a chance finding only [49][50]. The cytochrome P450 2C19 genotype did not also affect phenobarbital pharmacokinetics in neonates and infants [51].

4. Covariate-Based Phenobarbital Dosing

The routinely used phenobarbital dosing in neonates is based on body weight and consists of loading dose of 15–20 mg/kg followed by maintenance dose of 3–5 mg/kg per day. Several body weight-based dosing regimens or nomograms have been described. The intersection of these findings well corresponds to the above-mentioned dosing routines. Furthermore, doses at the lower limit of the suggested range should be preferred in patients with severe asphyxia, while the upper limit of the range should be targeted in neonates receiving ECMO support.

References

  1. Evans, D.; Levene, M. Neonatal seizures. Arch. Dis. Child Fetal Neonatal Ed. 1998, 78, F70–F75.
  2. El-Dib, M.; Soul, J.S. The use of phenobarbital and other anti-seizure drugs in newborns. Semin. Fetal Neonatal Med. 2017, 22, 321–327.
  3. Krishna, S.; Hutton, A.; Aronowitz, E.; Moore, H.; Vannucci, S.J. The effects of adding prophylactic phenobarbital to therapeutic hypothermia in the term-equivalent hypoxic-ischemic rat. Pediatr. Res. 2018, 83, 506–513.
  4. Papile, L.A.; Baley, J.E.; Benitz, W.; Cummings, J.; Carlo, W.A.; Eichenwald, E.; Kumar, P.; Polin, R.A.; Tan, R.C.; Committee on Fetus and Newborn; et al. Hypothermia and neonatal encephalopathy. Pediatrics 2014, 133, 1146–1150.
  5. Falsaperla, R.; Mauceri, L.; Pavone, P.; Barbagallo, M.; Vitaliti, G.; Ruggieri, M.; Pisani, F.; Corsello, G. Short-Term Neurodevelopmental Outcome in Term Neonates Treated with Phenobarbital versus Levetiracetam: A Single-Center Experience. Behav. Neurol. 2019, 2019, 3683548.
  6. Spagnoli, C.; Seri, S.; Pavlidis, E.; Mazzotta, S.; Pelosi, A.; Pisani, F. Phenobarbital for Neonatal Seizures: Response Rate and Predictors of Refractoriness. Neuropediatrics 2016, 47, 318–326.
  7. Zeller, B.; Giebe, J. Pharmacologic Management of Neonatal Seizures. Neonatal Netw. 2015, 34, 239–344.
  8. Pacifici, G.M. Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. Curr. Pediatr. Rev. 2016, 12, 48–54.
  9. Marsot, A.; Brevaut-Malaty, V.; Vialet, R.; Boulamery, A.; Bruguerolle, B.; Simon, N. Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. Fundam. Clin. Pharmacol. 2014, 28, 465–471.
  10. Lutz, I.C.; Allegaert, K.; de Hoon, J.N.; Marynissen, H. Pharmacokinetics during therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy: A literature review. BMJ. Paediatr. Open 2020, 4.
  11. Yozawitz, E.; Stacey, A.; Pressler, R.M. Pharmacotherapy for Seizures in Neonates with Hypoxic Ischemic Encephalopathy. Paediatr. Drugs 2017, 19, 553–567.
  12. Taburet, A.M.; Chamouard, C.; Aymard, P.; Chevalier, J.Y.; Costil, J. Phenobarbital protein binding in neonates. Dev. Pharmacol. Ther. 1982, 4, 129–134.
  13. Ehrnebo, M.; Agurell, S.; Jalling, B.; Boréus, L.O. Age differences in drug binding by plasma proteins: Studies on human foetuses, neonates and adults. Eur. J. Clin. Pharmacol. 1971, 3, 189–193.
  14. Kwan, P.; Brodie, M.J. Phenobarbital for the treatment of epilepsy in the 21st century: A critical review. Epilepsia 2001, 45, 1141–1149.
  15. Methaneethorn, J.; Leelakanok, L. Pharmacokinetic variability of phenobarbital: A systematic review of population pharmacokinetic analysis. Eur. J. Clin. Pharmacol. 2020.
  16. Anderson, B.J.; Holford, N.H. Understanding dosing: Children are small adults, neonates are immature children. Arch Dis Child 2013, 98, 737–744.
  17. Queensland Governmen. Queensland Clinical Guidelines. Available online: (accessed on 28 December 2020).
  18. Gilman, M.E.; Toback, J.W.; Gal, P.; Erkan, N.V. Individualizing phenobarbital dosing in neonates. Clin. Pharm. 1983, 2, 258–262.
  19. Gherpelli, J.L.; Cruz, A.M.; Tsanaclis, L.M.; Costa, H.P.; Garcia, T.G.; Segre, C.A.; Spina-Franca, A. Phenobarbital in newborns with neonatal seizures. A study of plasma levels after intravenous administration. Brain Dev. 1993, 15, 258–262.
  20. Nahata, M.C.; Masuoka, T.; Edwards, R.C. Developmental aspects of phenobarbital dosage requirements in newborn infants with seizures. J. Perinatol. 1988, 8, 318–320.
  21. Pauwels, S.; Allegaert, K. Therapeutic drug monitoring in neonates. Arch. Dis. Child. 2016, 101, 377–381.
  22. Jalling, B. Plasma concentrations of phenobarbital in the treatment of seizures in newborns. Acta. Paediatr. Scand. 1975, 64, 514–524.
  23. Touw, D.J.; Graafland, O.; Cranendonk, A.; Vermeulen, R.J.; van Weissenbruch, M.M. Clinical pharmacokinetics of phenobarbital in neonates. Eur. J. Pharm. Sci. 2000, 12, 111–116.
  24. Turhan, A.H.; Atici, A.; Okuyaz, C.; Uysal, S. Single enteral loading dose of phenobarbital for achieving its therapeutic serum levels in neonates. Croat. Med. J. 2010, 51, 215–218.
  25. Alonso Gonzalez, A.C.; Ortega Valin, L.; Santos Buelga, D.; Garcia Sanchez, M.J.; Santos Borbujo, J.; Monzon Corral, L.; Dominguez-Gil Hurle, A. Dosage programming of phenobarbital in neonatal seizures. J. Clin. Pharm. Ther. 1993, 18, 267–270.
  26. Fischer, J.H.; Lockman, L.A.; Zaske, D.; Kriel, R. Phenobarbital maintenance dose requirements in treating neonatal seizures. Neurology 1981, 31, 1042–1044.
  27. Filippi, L.; la Marca, G.; Cavallaro, G.; Fiorini, P.; Favelli, F.; Malvagia, S.; Donzelli, G.; Guerrini, R. Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: A pharmacokinetic study during whole body hypothermia. Epilepsia 2011, 52, 794–801.
  28. Oztekin, O.; Kalay, S.; Tezel, G.; Akcakus, M.; Oygur, N. Can we safely administer the recommended dose of phenobarbital in very low birth weight infants? Childs Nerv. Syst. 2013, 29, 1353–1357.
  29. Yukawa, M.; Yukawa, E.; Suematsu, F.; Takiguchi, T.; Ikeda, H.; Aki, H.; Mimemoto, M. Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants: An update. J. Clin. Pharm. Ther. 2011, 36, 704–710.
  30. Shellhaas, R.A.; Ng, C.M.; Dillon, C.H.; Barks, J.D.; Bhatt-Mehta, V. Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia. Pediatr. Crit. Care. Med. 2013, 14, 194–202.
  31. Sima, M.; Pokorna, P.; Hartinger, J.; Slanar, O. Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia. J. Clin. Pharm. Ther. 2018, 43, 196–201.
  32. Pitlick, W.; Painter, M.; Pippenger, C. Phenobarbital pharmacokinetics in neonates. Clin. Pharmacol. Ther. 1978, 23, 346–350.
  33. Grasela, T.H., Jr.; Donn, S.M. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. Dev. Pharmacol. Ther. 1985, 8, 374–383.
  34. Voller, S.; Flint, R.B.; Stolk, L.M.; Degraeuwe, P.L.J.; Simons, S.H.P.; Pokorna, P.; Burger, D.M.; de Groot, R.; Tibboel, D.; DINO study group. Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validation. Eur. J. Pharm. Sci. 2017, 109S, S90–S97.
  35. Moffett, B.S.; Weingarten, M.M.; Galati, M.; Placencia, J.L.; Rodman, E.A.; Riviello, J.J.; Kayyal, S.Y. Phenobarbital population pharmacokinetics across the pediatric age spectrum. Epilepsia 2018, 59, 1327–1333.
  36. Back, H.M.; Lee, J.B.; Han, N.; Goo, S.; Jung, E.; Kim, J.; Song, B.; An, S.H.; Kim, J.T.; Rhie, S.J.; et al. Application of Size and Maturation Functions to Population Pharmacokinetic Modeling of Pediatric Patients. Pharmaceutics 2019, 11, 259.
  37. Thibault, C.; Massey, S.L.; Naim, M.Y.; Abend, N.S.; Zuppa, A.F. Population Pharmacokinetics of IV Phenobarbital in Neonates After Congenital Heart Surgery. Pediatr. Crit. Care Med. 2020, 21, e557–e565.
  38. Michalickova, D.; Pokorna, P.; Tibboel, D.; Slanar, O.; Knibbe, C.A.J.; Krekels, E.H.J. Rapid Increase in Clearance of Phenobarbital in Neonates on Extracorporeal Membrane Oxygenation: A Pilot Retrospective Population Pharmacokinetic Analysis. Pediatr. Crit. Care Med. 2020, 21, e707–e715.
  39. Thibault, C.; Massey, S.L.; Abend, N.S.; Naim, M.Y.; Zorian, A.; Zuppa, A.F. Population Pharmacokinetics of Phenobarbital in Neonates and Infants on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy. J. Clin. Pharmacol. 2020, 61, 378–387.
  40. Gal, P.; Boer, H.R.; Toback, J.; Erkan, N.V. Phenobarbital dosing in neonates and asphyxia. Neurology 1982, 32, 788–789.
  41. Gal, P.; Toback, J.; Erkan, N.V.; Boer, H.R. The influence of asphyxia on phenobarbital dosing requirements in neonates. Dev. Pharmacol. Ther. 1984, 7, 145–152.
  42. Pokorna, P.; Posch, L.; Sima, M.; Klement, P.; Slanar, O.; van den Anker, J.; Tibboel, D.; Allegaert, K. Severity of asphyxia is a covariate of phenobarbital clearance in newborns undergoing hypothermia. J. Matern. Fetal. Neonatal Med. 2018, 32, 2302–2309.
  43. Pokorna, P.; Michalickova, D.; Voller, S.; Hronova, K.; Tibboel, D.; Slanar, O.; Krekels, E.H. Severity parameters for asphyxia or hypoxic-ischemic encephalopathy do not explain interindividual variability in the pharmacokinetics of phenobarbital in newborns treated with therapeutic hypothermia. Minerva Pediatr. 2020.
  44. Van den Broek, M.P.; Groenendaal, F.; Toet, M.C.; van Straaten, H.L.; van Hasselt, J.G.; Huitema, A.D.; de Vries, L.S.; Egberts, A.C.; Rademaker, C.M. Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: A thermopharmacological approach. Clin. Pharmacokinet. 2012, 51, 671–679.
  45. Favie, L.M.A.; de Haan, T.R.; Bijleveld, Y.A.; Rademaker, C.M.A.; Egberts, T.C.G.; Nuytemans, D.; Mathot, R.A.A.; Groenendaal, F.; Huitema, A.D.R. Prediction of Drug Exposure in Critically Ill Encephalopathic Neonates Treated with Therapeutic Hypothermia Based on a Pooled Population Pharmacokinetic Analysis of Seven Drugs and Five Metabolites. Clin. Pharmacol. Ther. 2020, 108, 1098–1106.
  46. Pokorna, P.; Sima, M.; Vobruba, V.; Tibboel, D.; Slanar, O. Phenobarbital pharmacokinetics in neonates and infants during extracorporeal membrane oxygenation. Perfusion 2018, 33, 80–86.
  47. Dillman, N.O.; Messinger, M.M.; Dinh, K.N.; Placencia, J.L.; Moffett, B.S.; Guaman, M.C.; Erklauer, J.C.; Kaiser, J.R.; Wilfong, A.A. Evaluation of the Effects of Extracorporeal Membrane Oxygenation on Antiepileptic Drug Serum Concentrations in Pediatric Patients. J. Pediatr. Pharmacol. Ther. 2017, 22, 352–357.
  48. Sima, M.; Pokorna, P.; Hronova, K.; Slanar, O. Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. Physiol. Res. 2015, 64, S513–S519.
  49. Sima, M.; Slanar, O. Impact of drug-drug interactions on phenobarbital pharmacokinetics in pediatric patients. Epilepsia 2019, 60, 1266–1267.
  50. Moffett, B.S. Impact of drug-drug interactions on phenobarbital pharmacokinetics in pediatric patients—Response. Epilepsia 2019, 60, 1268.
  51. Lee, S.M.; Chung, J.Y.; Lee, Y.M.; Park, M.S.; Namgung, R.; Park, K.I.; Lee, C. Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures. Arch. Dis. Child. 2012, 97, 569–572.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Pharmacology & Pharmacy
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Martin Šíma
View Times: 2.1K
Revisions: 2 times (View History)
Update Date: 22 Apr 2021
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback